Literature DB >> 27597874

Diversity of Molecular Mechanisms Conferring Carbapenem Resistance to Pseudomonas aeruginosa Isolates from Saudi Arabia.

Mohamed H Al-Agamy1, Katy Jeannot2, Taghrid S El-Mahdy3, Hassan A Samaha4, Atef M Shibl5, Patrick Plésiat6, Patrice Courvalin7.   

Abstract

Background. This study described various molecular and epidemiological characters determining antibiotic resistance patterns in Pseudomonas aeruginosa isolates. Methods. A total of 34 carbapenem-resistant P. aeruginosa clinical isolates were isolated from samples collected at a tertiary hospital in Riyadh, Saudi Arabia, from January to December 2011. Susceptibility testing, serotyping, molecular characterization of carbapenem resistance, and pulsed-field gel electrophoresis (PFGE) were performed. Results. All isolates were resistant to ceftazidime, and more than half were highly resistant (minimum inhibitory concentration (MIC) > 256 mg/L). Fifteen isolates had MIC values ≥64 mg/L for any of the carbapenems examined. Vietnamese extended-spectrum β-lactamase (VEB-1) (n = 16/34) and oxacillinase (OXA-10) (n = 14/34) were the most prevalent extended-spectrum β-lactamase and penicillinase, respectively. Verona imipenemase (VIM-1, VIM-2, VIM-4, VIM-11, and VIM-28) and imipenemase (IMP-7) variants were found in metallo-β-lactamase producers. A decrease in outer membrane porin gene (oprD) expression was seen in nine isolates, and an increase in efflux pump gene (MexAB) expression was detected in five isolates. Six serotypes (O:1, O:4, O:7, O:10, O:11, and O:15) were found among the 34 isolates. The predominant serotype was O:11 (16 isolates), followed by O:15 (nine isolates). PFGE analysis of the 34 carbapenem-resistant P. aeruginosa isolates revealed 14 different pulsotypes. Conclusions. These results revealed diverse mechanisms conferring carbapenem resistance to P. aeruginosa isolates from Saudi Arabia.

Entities:  

Year:  2016        PMID: 27597874      PMCID: PMC4997076          DOI: 10.1155/2016/4379686

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


1. Background

Pseudomonas aeruginosa is a pathogen emerging as a frequent cause of nosocomial infections, especially pneumonia and sepsis, with mortality rates of 27–48% in critically ill patients [1, 2]. The increasing prevalence of infections caused by multidrug-resistant (MDR) P. aeruginosa strains is associated with significant morbidity and mortality [3]. Management of the infections is difficult since strains often display intrinsic and acquired resistance to multiple classes of antibiotics, severely limiting therapeutic options [4]. One feature of P. aeruginosa isolates is their high level of intrinsic resistance to a number of antimicrobial agents. The broad-spectrum resistance of these organisms is largely due to low outer membrane permeability [5] and to efflux systems [6]. Moreover, they possess inducible, chromosomally encoded AmpC cephalosporinase belonging to Ambler class C enzymes [7]. Extended-spectrum β-lactamases (ESBLs), including TEM, SHV, PER, VEB, GES, OXA-2, and OXA-10 enzymes, are increasingly reported in P. aeruginosa [8, 9]. This situation has led to the use of carbapenems as drugs of last resort for treating infections caused by these bacteria. However, the emergence and increasing frequency of isolation of carbapenem-resistant P. aeruginosa strains is alarming [10]. Impermeability arising via the loss of outer membrane porin (OprD), upregulation of an active efflux pump (MexAB-OprM), and production of metallo-β-lactamases (MBLs) are of great concern [4, 11]. Several types of MBL enzymes, including imipenemase (IMP), Verona imipenemase (VIM), New Delhi MBL (NDM), Seoul imipenemase (SIM), São Paulo MBL (SPM), German imipenemase (GIM), Adelaide imipenemase (AIM), and Dutch imipenemase (DIM), have been identified in P. aeruginosa [12]. The genes responsible for the production of MBLs are typically part of class 1 integron structures, which carry other resistance gene cassettes. Hence, isolates producing MBLs are often resistant to different groups of antimicrobial agents, and the resistance can be transferred to various types of bacteria [13, 14]. In this study, we investigated the molecular epidemiology of carbapenem-resistant P. aeruginosa isolates obtained from January through December 2011 from patients hospitalized in a tertiary hospital in Riyadh, Saudi Arabia.

2. Methods

2.1. Bacterial Strains

Thirty-four carbapenem-resistant P. aeruginosa isolates were included in this study. The strains were isolated over a one-year period, from January through December 2011, from patients hospitalized in a tertiary hospital in Riyadh, Saudi Arabia. The isolates were identified as P. aeruginosa in the clinical laboratory using the VITEK 2 system (bioMérieux, Marcy l'Etoile, France).

2.2. Susceptibility Testing

Susceptibility testing to 10 antimicrobial agents, imipenem (IPM), meropenem (MER), doripenem (DOR), ceftazidime (CAZ), amikacin (AN), tobramycin (TM), ciprofloxacin (CIP), colistin (CS), aztreonam (ATM), and ticarcillin (TIC), was performed by an agar dilution method, and the data were interpreted according to the CLSI breakpoints [20].

2.3. Serotyping of Isolates

The O-serotypes were determined by a slide agglutination test using four pools (OMA, OMC, OME, and OMF) and 20 monovalent antisera, O1 to O20 (Sanofi Diagnostics Pasteur), according to the manufacturer's recommendations.

2.4. MBL Screening

The isolates were screened for MBL production by a double-disk (10 μg of IPM and 2.5 μM ethylenediaminetetraacetic acid) synergy test [20]. A synergistic inhibition zone visible between the two disks indicated a positive result.

2.5. Detection of β-Lactamase (bla) Genes

The primers used in this study are shown in Table 1. The polymerase chain reaction (PCR) amplification of genes for Ambler classes A, B, and D β-lactamase enzymes was performed using specific primers for bla GES, bla VEB, bla PER, bla PSE, bla CTX-M, bla TEM, bla SHV, bla KPC, bla IMP, bla VIM, bla NDM, bla OXA-I, and bla OXA-II [15-19], followed by sequencing reactions using the Sanger method [21]. Plasmid DNA was extracted according to the Kieser protocol [22].
Table 1

Primers used in this study.

Gene Primer Sequence (5′-3′)Reference
bla TEM MultiTSO-T_forMultiTSO-T_revCATTTCCGTGTCGCCCTTATTCCGTTCATCCATAGTTGCCTGAC[15]

bla SHV MultiTSO-S_forMultiTSO-S_revAGCCGCTTGAGCAAATTAAACATCCCGCAGATAAATCACCAC[15]

bla CTX-M CTX-M-U1 CTX-M-U2ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG[16]

bla VEB MultiVEB_forMultiVEB_revCATTTCCCGATGCAAAGCGTCGAAGTTTCTTTGGACTCTG[15]

bla PER MultiPER_forMultiPER_revGCTCCGATAATGAAAGCGTTTCGGCTTGACTCGGCTGA[15]

bla GES MultiGES_forMultiGES_revAGTCGGCTAGACCGGAAAGTTTGTCCGTGCTCAGGAT[15]

bla VIM VIM-FVIM-RGATGGTGTTTGGTCGCATACGAATGCGCAGCACCAG[17]

bla IMP IMP-FIMP-RGGAATAGAGTGGCTTAAYTCTCGGTTTAAYAAAACAACCACC[17]

bla NDM NDM-FNDM-RGGTTTGGCGATCTGGTTTTCCGGAATGGCTCATCACGATC[17]

bla KPC KPC-FmKPC-RmCGTCTAGTTCTGCTGTCTTGCTTGTCATCCTTGTTAGGCG[17]

bla OXA-I group OXA-10 FOXA-10 RTCAACAAAT CGC CAGAGAAG TCC CAC ACC AGA AAA ACC AG[18]

bla OXA-II groupOXA-2 FOXA-2 RAAGAAACGCTAC TCGCCT GCCCACTCAACCCATCCTACCC[18]

bla PSE PSE-FPSE-RACC GTA TTG AGC CTG ATT TAATT GAA GCC TGT GTT TGA GC[18]

mexA MexARTFMexARTR2CAAGCAGAAGGCCATCCTCCGGTAATGATCTTGTCGCCG[19]

oprD OprDRTF3OprDRTR3GAAGCCAAGTACGTGGTCCAGCAGGATCGACAGCGGATAGTC[19]

rpsL RpsLF1RpsLR1GCAACTATCAACCAGCTGGTGGCTGTGCTCTTGCAGGTTGTG[19]

2.6. Pulsed-Field Gel Electrophoresis

Clonal relatedness of the P. aeruginosa isolates was evaluated by SpeI macrorestriction analysis of genomic DNA, followed by pulsed-field gel electrophoresis (PFGE) [23, 24]. DNA fragments were separated for 20 h at 6 V/cm, 120° included angle, at 14°C using a CHEF-DR II System (Bio-Rad), with the initial and final pulse times of 1 and 35 s, respectively. P. aeruginosa strain PAO1 was used as a reference strain. The band patterns that were more than 80% identical were considered related.

2.7. RNA Extraction and Real-Time RT-PCR to Measure oprD and mexA Expression Levels

For RNA isolation, strains were grown in LB broth to the logarithmic phase identified by the optical density at 600 nm, followed by centrifugation. Total RNA was prepared using the TRIzolMax method (Invitrogen, Carlsbad, CA) according to the manufacturer's recommendations. RNase-free DNase (Ambion, Austin, TX) was used to remove DNA. The removal of contaminating DNA was verified by PCR in the absence of reverse transcriptase. Real-time reverse transcription- (RT-) PCR was performed in duplicate using independent RNA extractions and the QuantiTect SYBR Green RT-PCR kit (Qiagen, Inc., Valencia, CA). The primers used for the detection of the mexA and oprD transcripts are listed in Table 1. Expression levels of the endogenous control gene, rpsL (Table 1), were used to normalize the data. A wild-type strain of P. aeruginosa, PAO1, was used as a reference [25]. The genes were considered to be up- or downregulated when the amounts of RNA transcripts were at least twofold higher or lower, respectively, than those in PAO1 [26].

3. Results

3.1. Antibiotic Susceptibility

The 34 P. aeruginosa strains were highly resistant to TIC, with the minimum inhibitory concentration at which 90% of the isolates were inhibited (MIC90) of ≥256 mg/L (Table 2). All isolates were CAZ-resistant (MICs: 32 to >256 mg/L), and 23 of them were highly resistant (MICs > 256 mg/L). All isolates were also resistant to one or more of the carbapenems tested (IPM, MER, and DOR). Thirteen of the 34 isolates (38%) were highly resistant to IPM (MICs ≥ 64 mg/L). ATM resistance was observed in 23 of the 34 isolates (67.65%), and the MIC values ranged from 32 to >512 mg/L. The resistance levels to TM, AN, and CIP were variable. Only one strain was resistant to CS. More than half of the isolates (18 of 34) were resistant to all tested antimicrobials, except CS (Table 2).
Table 2

Serotypes, resistance patterns, and phenotypic and genotypic characterization of Pseudomonas aeruginosa isolates.

Isolate SerotypeMinimum inhibitory concentration (mg/L)a Genotypic profile PFGE typePlasmid
IPMMERDORCAZCIPTMCSANATMTIC
1O:111286464>256>16>128112816>1,024IMP-7, OXA-10, VIM-11ANo
2O:11326432>256>16>128212816>1,024IMP-7, OXA-10, VIM-11ANo
3O:1112812864>256>1612813216>1,024IMP-7, OXA-10, VIM-11ANo
4O:11>256>128>128>256>166411616>1,024IMP-7, OXA-10, VIM-2BNo
5O:11>256>128>1281280.5>1282328>1,024VIM-4, IMP-7, OXA-2CNo
6O:11>256>128>1282560.511648>1,024VIM-4, IMP-7, OXA-2CNo
7O:11>256>128128128>16>128825632>1,024VIM-4, IMP-7, OXA-2DNo
8O:7646432256>16>12821288>1,024VIM-28E>50 kb
9NT12812864>256>16642>256>512>1,024OXA-10, VEB-1a, GES-4, VIM-1ANo
10O:416164>256>16642>256128>1,024IMP-7, OXA-10, VIM-11ANo
11O:15323232>256>16128264>512>1,024OXA-10, VEB-1aF50 kb
12O:153232>128>256>161282325121,024OXA-10, VEB-1aF50 kb
13O:15323216>256>16>1282128>512>1,024OXA-10, VEB-1aF50 kb
14O:15323216>256>1664132>512>1,024OXA-10, VEB-1aF50 kb
15O:1532328>256>1664132>5121,024OXA-10, VEB-1aF50 kb
16O:15323216>256>16128264>512 >1,024OXA-10, VEB-1aF50 kb
17O:153212864>256>1664132>512>1,024OXA-10, VEB-1aF50 kb
18O:15>25612864>256>1664232>512>1,024OXA-10, VEB-1aF50 kb
19O:15323216>256>16128232>512>1,024OXA-10, VEB-1aF50 kb
20O:11128128128>256>166413216>1,024IMP-7GNo
21O:11163232>256>16641168512IMP-7HNo
22O:11163216>256>1632216>512>1,024VEB-1b, OprD−, MexAB+INo
23O:1116164>256>1664264>5121,024VEB-1b, OprD−, MexAB+JNo
24O:1116168>256>16642325121,024VEB-1bJNo
25O:11>2563216>256>25664264256>1,024VEB-1b, OprD−JNo
26O:1116164>256>1632232>512>1,024VEB-1bJNo
27O:111384>256>16322325121,024VEB-1bJNo
28O:432322128412811616>1,024GES-1, OprD−KNo
29O:412812864256>16642>256321,024GES-6LNo
30O:1016168320.3124512256OprD−MNo
31O:432168640.511464256OprD−, MexAB+NNo
32O:10888640.31226464OprD−NNo
33O:1164323264111864128OprD−, MexAB+NNo
34O:13216481642816>1,024OprD−, PSE-1, MexAB+NNo

aMinimum inhibitory concentration interpretation according to CLSI (2014) recommendations [20].

IPM: imipenem; MER: meropenem; DOR: doripenem; CAZ: ceftazidime; AN: amikacin; TM: tobramycin; CIP: ciprofloxacin; CS: colistin; ATM: aztreonam; TIC: ticarcillin.

NT: nontypable.

OprD−: downregulation of OprD porin.

MexAB+: upregulation of MexAB.

3.2. Genotyping and Resistance Mechanisms

The genotyping analysis by PFGE was performed for all 34 carbapenem-resistant P. aeruginosa isolates, and 14 PFGE profiles (A–N) were identified (Table 2). Five of the 14 clones were represented by 73.5% (n = 25) of all isolates. The most common clones were F (n = 9), A (n = 5), J (n = 5), N (n = 4), and C (n = 2). The other nine clones were represented by one isolate each. Diverse resistance mechanisms leading to β-lactam resistance were identified in the 34 isolates (Table 2). Vietnamese-type ESBLs (VEB-1a and VEB-1b) were found in 16 strains. Oxacillinase- (OXA-10- and OXA-2-) and PSE-type penicillinases were also detected in the present study. Whereas OXA-10 (n = 14) was more prevalent, only three strains were found to have OXA-2, and one strain was found to have PSE-1. Two MBL types, VIM and/or IMP, were detected in 12 isolates; each was carried by nine isolates, while seven isolates harbored both VIM and IMP. Five variants of VIM were identified (VIM-1, VIM-2, VIM-4, VIM-11, and VIM-28); however, only one variant of IMP (IMP-7) was detected. All MBL-carrying strains were positive in the MBL phenotypic test, while the test gave negative results for the remaining isolates. Moreover, Guiana ESBL (GES) was detected in three isolates, each producing a different variant of the enzyme (GES-1, GES-4, and GES-6). Downregulation of OprD porin was detected in nine isolates. In two isolates, this was the only genotypic trait detected, while, in seven other isolates, it was associated with upregulation of the MexAB-OprM efflux pump (two isolates) or with the presence of β-lactamase bla VEB-1b and bla GES-1 genes (two isolates), or with both presence of a β-lactamase (VEB-1b or PSE-1) and upregulation of MexAB-OprM (three isolates). Nine isolates exhibited only one resistance mechanism. Three of them had an MBL, either VIM or IMP, and were ATM-susceptible but carbapenem-resistant. GES was carried by one isolate, whereas three isolates carried VEB-1b only, and the remaining two isolates only downregulated OprD porin. PCR amplification of bla CTX-M, bla TEM, bla SHV, bla KPC, and bla NDM showed negative results for all isolates.

3.3. Serotyping

Six serotypes were identified among the 34 isolates, including O1, O4, O7, O10, O11, and O15 (Table 2). The predominant P. aeruginosa serotype was O11 (16/34, 47%), followed by O15 (9/34, 26.5%) and O4 (4/34, 11.7%). Only one strain (number 9) was nontypable by the slide agglutination test. All serotype O15 strains (n = 9) were found to have the same pulsotype (F) and the same mechanism of resistance (OXA-10 and VEB-1a). In the present study, 10 isolates were found to harbor a plasmid among the 34 isolates examined for plasmids. The 10 plasmid-carrying isolates produced VIM-28 (clone E, O7, isolate number 8) or OXA-10 and VEB-1a (clone F, O15, isolates numbers 11–19).

4. Discussion

The present study clearly demonstrated a high level of resistance to carbapenems in the isolates obtained from patients from a tertiary hospital in Riyadh, Saudi Arabia. Having 16 isolates (47%) with a MIC of ≥64 mg/L for one or more of the carbapenems tested is worrisome. Much lower carbapenem MICs were previously reported in Saudi Arabia [27], with a high prevalence of IPM-resistant (91% of 33 isolates) P. aeruginosa isolates, yet none reached the IPM MIC values higher than 32 mg/L. In the above study, two P. aeruginosa isolates (6%) were found to be CS-resistant; fortunately, only one (2.9%) CS resistance was observed in our isolates. It should be mentioned that the authors [27] used the CS resistance breakpoint of >2 mg/L in accordance with the CLSI, 2006 guidelines. However, in our study, the resistance breakpoint was >4 mg/L following the CLSI, 2014 recommendations [20]. Consequently, based on this definition, we had one CS-resistant isolate (isolate number 7), which showed a MIC value of 8 mg/L. It is important, when defining resistant strains, to report the reference used for the breakpoint, especially for rare antibiotic resistance phenotypes, such as CS resistance in P. aeruginosa. The diversity of the resistance mechanisms observed in our isolates reveals the different ways by which P. aeruginosa can acquire drug resistance. In our study, 12 of the 34 carbapenem-resistant isolates (35.3%) expressed MBLs, either VIM or IMP. This proportion is smaller than that reported in a study from Egypt, in which the carriage rate of MBLs in carbapenem-resistant P. aeruginosa isolates was 69%, and most of them were bla VIM-2 carriers [28]. Furthermore, in two previous studies from Saudi Arabia, MBLs were detected in 41% (16 of 39 isolates) and 60% (15 of 25 isolates) of IPM-resistant isolates, and VIM was found in all MBL-positive isolates [29]. Recently, it was also found in Saudi Arabia that only 11 of 39 carbapenem-resistant P. aeruginosa isolates carried carbapenemase genes (bla VIM and bla GES-5), while the rest (28/39, 72%) had no genes to explain the resistance seen [30]. Although carbapenem resistance can also be driven by inactivation of OprD, upregulation of the MexAB-OprM efflux system, or other, unknown, resistance mechanisms, these mechanisms were not investigated in the above study. In our study, 13 of the 34 carbapenem-resistant strains (38%) revealed no known resistance mechanism to explain their resistance since they harbored bla VEB-1 alone or with bla OXA-10 or harbored bla GES-6 alone, and these are not carbapenemase-encoding genes. These strains also produced negative results in the MBL phenotypic test, suggesting other resistance mechanisms responsible for their carbapenem resistance. This finding was also confirmed by the ATM resistance found in all 13 isolates, suggesting that MBLs were not responsible for their carbapenem resistance since MBLs alone do not confer resistance to ATM [12]. It should be noted that transcriptional or posttranscriptional regulation of OprD may also happen leading to loss or reduction of OprD production even if there is no decrease in oprD expression (but this is not examined in our study). Additionally, the current study is in accordance with a previous review of Gram-negative bacteria found in Saudi Arabia [31], in which the authors reported that, in P. aeruginosa, VEB-like enzymes were most common (in 47% of our isolates), VIM appeared to be the most common MBL (in 29.4% of our isolates), and OXA-10 was frequent (in 44% of our isolates). The present study is the second report of VIM-28, which was first reported in P. aeruginosa from Egypt, another Middle Eastern country in the western vicinity of Saudi Arabia [32]. Our findings that all nine serotype O:15 strains (26.5%) belonged to a single pulsotype (F) and all had the same resistance pattern, harboring OXA-10 + VEB-1a, are similar to the data from a previous UK study [33]. The UK study showed that 15 of 32 bla VEB-positive P. aeruginosa isolates (47%) belonged to serotype O:15, had a single PFGE type, carried a VEB-1a variant, but with coexistence of VIM-10, and presented the same resistance pattern. In earlier studies [34, 35], the relationship between P. aeruginosa serotypes and antibiotic resistance patterns was investigated, and it was noticed that some serotypes were more associated with resistance to certain antibiotics, although the studies revealed different findings. Additionally, it was also reported that certain serotypes were associated with specific P. aeruginosa sequence-type (ST) clones [36, 37]. Guzvinec et al. [37] reported that clones ST235, ST111, and ST132 included serotypes O:11, O:12, and O:6, respectively, and that serotype O:11 was predominant (41% of 103 isolates). In the present study, the O:11 serotype was also the most prevalent serotype (47% of our isolates), although these isolates were found to have diverse PFGE types and different resistance mechanisms.

5. Conclusions

The increasing prevalence of infections caused by carbapenem-resistant and MDR P. aeruginosa strains is a serious problem, and it is associated with significant morbidity and mortality [3]. The study sets off the alarm of a high level of resistance to carbapenems (47% of isolates with MICs ≥64 mg/L). Further studies of the molecular basis of P. aeruginosa resistance in our region are needed to gain a better understanding of the complexity of resistance mechanisms in this organism. The finding that 38% of our isolates revealed no resistance mechanism to explain the carbapenem resistance highlights the urgent demand for more studies to investigate the unknown resistance mechanisms conferring carbapenem resistance to P. aeruginosa.
  35 in total

Review 1.  Metallo-β-lactamases: a last frontier for β-lactams?

Authors:  Giuseppe Cornaglia; Helen Giamarellou; Gian Maria Rossolini
Journal:  Lancet Infect Dis       Date:  2011-05       Impact factor: 25.071

Review 2.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

3.  Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates.

Authors:  Abdulkader F Tawfik; Atef M Shibl; Mohamed A Aljohi; Musaad A Altammami; Mohamed H Al-Agamy
Journal:  Burns       Date:  2012-02-19       Impact factor: 2.744

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Serotypes of Pseudomonas aeruginosa in clinical specimens in relation to antibiotic susceptibility.

Authors:  N J Legakis; M Aliferopoulou; J Papavassiliou; M Papapetropoulou
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

6.  Molecular typing indicates an important role for two international clonal complexes in dissemination of VIM-producing Pseudomonas aeruginosa clinical isolates in Hungary.

Authors:  Balázs Libisch; Joseph Watine; Boglárka Balogh; Mária Gacs; Mónika Muzslay; Gitta Szabó; Miklós Füzi
Journal:  Res Microbiol       Date:  2008-01-11       Impact factor: 3.992

Review 7.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 8.  The increasing threat of Pseudomonas aeruginosa high-risk clones.

Authors:  Antonio Oliver; Xavier Mulet; Carla López-Causapé; Carlos Juan
Journal:  Drug Resist Updat       Date:  2015-08-10       Impact factor: 18.500

9.  Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.

Authors:  Daniel J Wolter; Jennifer A Black; Philip D Lister; Nancy D Hanson
Journal:  J Antimicrob Chemother       Date:  2009-05-25       Impact factor: 5.790

10.  Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.

Authors:  Andrea Endimiani; Francesco Luzzaro; Beatrice Pini; Gianfranco Amicosante; Gian Maria Rossolini; Antonio Q Toniolo
Journal:  BMC Infect Dis       Date:  2006-03-16       Impact factor: 3.090

View more
  12 in total

1.  Identification of the Pseudomonas aeruginosa O17 and O15 O-Specific Antigen Biosynthesis Loci Reveals an ABC Transporter-Dependent Synthesis Pathway and Mechanisms of Genetic Diversity.

Authors:  Steven M Huszczynski; Youai Hao; Joseph S Lam; Cezar M Khursigara
Journal:  J Bacteriol       Date:  2020-09-08       Impact factor: 3.490

2.  First report of VIM metallo-β-lactamase production in Escherichia coli and Klebsiella pneumoniae clinical isolates from Gaza Strip, Palestine.

Authors:  Ghassan Tayh; Daram Nagarjuna; Rym Ben Sallem; Vivek Verma; Sarra Chairat; Abdellatif Boudabous; Manisha Yadav; Karim Ben Slama
Journal:  Germs       Date:  2020-03-02

Review 3.  Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region.

Authors:  Mahmood Al-Orphaly; Hamad Abdel Hadi; Faiha Kamaleldin Eltayeb; Hissa Al-Hail; Bincy Gladson Samuel; Ali A Sultan; Sini Skariah
Journal:  mSphere       Date:  2021-05-19       Impact factor: 4.389

4.  Draft Genome Sequence of an IMP-7-Producing Pseudomonas aeruginosa Bloodstream Infection Isolate from Australia.

Authors:  K L McCarthy; A Jennison; A M Wailan; D L Paterson
Journal:  Genome Announc       Date:  2017-07-06

5.  Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains.

Authors:  Amani M Alnimr; Aisha M Alamri
Journal:  J Taibah Univ Med Sci       Date:  2020-05-12

6.  Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations.

Authors:  Raghdaa A Ramadan; Manar G Gebriel; Heba M Kadry; Ahmed Mosallem
Journal:  Infect Drug Resist       Date:  2018-08-22       Impact factor: 4.003

7.  Clinical outcomes, molecular epidemiology and resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa isolated from bloodstream infections from Qatar.

Authors:  Mazen A Sid Ahmed; Jemal M Hamid; Ahmed A Husain; Hamad Abdel Hadi; Sini Skariah; Ali A Sultan; Emad Bashir Ibrahim; Abdul Latif Al Khal; Bo Soderquist; Jana Jass; Ali S Omrani
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

8.  Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Mazen A Sid Ahmed; Faisal Ahmad Khan; Hamad Abdel Hadi; Sini Skariah; Ali A Sultan; Abdul Salam; Abdul Latif Al Khal; Bo Söderquist; Emad Bashir Ibrahim; Ali S Omrani; Jana Jass
Journal:  Antibiotics (Basel)       Date:  2022-01-19

Review 9.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

10.  Genomic Characterization of Carbapenem-Non-susceptible Pseudomonas aeruginosa Clinical Isolates From Saudi Arabia Revealed a Global Dissemination of GES-5-Producing ST235 and VIM-2-Producing ST233 Sub-Lineages.

Authors:  Michel Doumith; Sarah Alhassinah; Abdulrahman Alswaji; Maha Alzayer; Essa Alrashidi; Liliane Okdah; Sameera Aljohani; Hanan H Balkhy; Majed F Alghoribi
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.